Premium
Successful treatment with daratumumab for post‐HSCT refractory hemolytic anemia
Author(s) -
EvenOr Ehud,
Naser Eddin Adeeb,
Shadur Bella,
Dinur Schejter Yael,
Najajreh Mohammad,
Zelig Orly,
Zaidman Irina,
Stepensky Polina
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28010
Subject(s) - daratumumab , medicine , autoimmune hemolytic anemia , hematopoietic stem cell transplantation , refractory (planetary science) , myelofibrosis , immunology , antibody , anemia , monoclonal antibody , transplantation , bone marrow , physics , astrobiology
Autoimmune cytopenias (AIC) following allogeneic hematopoietic stem cell transplantation (HSCT) may cause significant morbidity and mortality and are often challenging to treat. We present a case of a pediatric patient with primary myelofibrosis of infancy caused by VPS45 protein deficiency, who developed severe refractory hemolytic anemia and immune‐mediated thrombocytopenia 3.5 months following HSCT. After the failure of several treatments, he received daratumumab, an anti‐CD38 specific antibody, and demonstrated fast and sustained response. The only side effect was delayed recovery of humoral immunity. Daratumumab, by targeting antibody‐producing plasma cells, may be a valid treatment option for refractory post‐HSCT AIC.